References
- Choi WW, Lewis MM, Lawson D. (2005). Angiogenic and lymphangiogenic microvessel density in breast carcinoma: correlation with clinicopathologic parameters and VEGF family gene expression. Mod Pathol 18:143–52.
- Donnem T, Al-Saad S, Al-Shibli K, et al. (2008). Prognostic impact of platelet-derived growth factors in non-small cell lung cancer tumor and stromal cells. J Thorac Oncol 3:963–70.
- Han H, Silverman JF, Santucci TS. (2001). Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis. Ann Surg Oncol 8:72–9.
- Hansell P, Mainne TE, Borgstrom P. (1995). Selective binding of platelet factor 4 to regions of active angiogenesis in vivo. Am J Physiol 269:H829–36.
- Jain L, Vargo CA, Danesi R, et al. (2009a). The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors. Mol Cancer Ther 8:2496–508.
- Jain RK, Duda DG, Willett CG, et al. (2009b). Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 6:327–38.
- Jemal A, Bray F, Center MM, et al. (2011). Global cancer statistics. CA Cancer J Clin 61:69–90.
- Kadota K, Huang CL, Liu D, et al. (2008). The clinical significance of lymphangiogenesis and angiogenesis in non-small cell lung cancer patients. Eur J Cancer 44:1057–67.
- Kreuter M, Kropff M, Fischaleck A, et al. (2009). Prognostic relevance of angiogenesis in stage III NSCLC receiving multimodality treatment. Eur Respir J 33:1383–8.
- Maeda A, Nakata M, Yasuda K, et al. (2013). Influence of vascular endothelial growth factor single nucleotide polymorphisms on non-small cell lung cancer tumor angiogenesis. Oncol Rep 29:39–44.
- Meert AP, Paesmans M, Martin B, et al. (2002). The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 87:694–701.
- Mineo TC, Ambrogi V, Baldi A, et al. (2004). Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumour vessel invasion after radical surgery for IB-IIA non-small cell lung cancer. J Clin Pathol 57:591–7.
- O’Byrne KJ, Koukourakis MI, Giatromanolaki A, et al. (2000). Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small cell lung cancer. Br J Cancer 82:1427–32.
- Oldenhuis CN, Oosting SF, Gietema JA, de Vries EG. (2008). Prognostic versus predictive value of biomarkers in oncology. Eur J Cancer 44:946–53.
- Pathak AP, Hochfeld WE, Goodman SL, Pepper MS. (2008). Circulating and imaging markers for angiogenesis. Angiogenesis 11:321–35.
- Piuda JM, Parkinson DR. (1996). Clinical implications of tumor-associated neovascularization and current antiangiogenic strategies for the treatment of malignancies of pancreas. Cancer 78:680–7.
- Spaks A, Jaunalksne I, Donina S, et al. (2012a). Dynamics of CXC group chemokine platelet factor 4 (PF4) plasma levels in non-small cell lung cancer (NSCLC). J Transl Med 10:P9.
- Spaks A, Jaunalksne I, Basko J, et al. (2012b). Introducing the new biomarker research approach into practice: preliminary data from CXCL4 chemokine study in non-small cell lung cancer (NSCLC). Lung Cancer 77:P26.
- Spaks A, Basko J, Jaunalksne I, et al. (2012c). Potential association of platelet factor 4 (PF4) with angiogenesis in non-small cell lung cancer (NSCLC). J Thorac Oncol 6:P108.
- Strieter RM, Addison CL, Ehlert JE, et al. (1999). Use of immunodeficient mice for the evaluation of CXC chemokines in the regulation of tumor-associated angiogenesis. ILAR J 40:175–82.
- Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E, eds. (1999). Histological typing of lung and pleural tumours. In collaboration with pathologists in 14 countries. 3rd ed. Geneva: World Health Organization.